Neonatal mass screening for 21-hydroxylase deficiency

Area of Science:

• Endocrinology
• Genetics
• Pediatrics

Background:

• Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is an inherited disorder with significant phenotypic variability.
• The salt-wasting (SW) form presents with life-threatening adrenal insufficiency in neonates, necessitating early detection.
• Current neonatal screening for 21-OHD faces challenges with low positive predictive value (PPV), particularly in preterm infants.

Purpose of the Study:

• To review current knowledge on neonatal mass screening for 21-OHD.
• To highlight the importance of screening for preventing mortality and misdiagnosis.
• To explore methods for improving the accuracy of neonatal screening programs.

Main Methods:

• Literature review of current practices and advancements in neonatal screening for 21-OHD.
• Discussion of the role of second-tier testing to enhance diagnostic accuracy.
• Analysis of the benefits and limitations of existing screening protocols.

Main Results:

• Neonatal screening for 21-OHD is implemented globally to prevent severe health consequences.
• Low positive predictive value (PPV) is a significant issue, especially in preterm infants.
• Liquid chromatography-tandem mass spectrometry (LC-MS/MS) shows promise as a second-tier test to improve PPV.

Conclusions:

• Neonatal screening for 21-OHD is vital for early intervention and improved patient outcomes.
• Enhancing screening accuracy is essential to reduce false positives and unnecessary follow-ups.
• LC-MS/MS offers a potential solution to increase the reliability of neonatal 21-OHD screening.